TC Biopharm
TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies. We have a strong focus on chimeric antigen receptor (CAR) modified GDT cells with the aim of treating cancer and major viral diseases. We have a unique technology with a demonstrable safety profile and established intellectual property rights for the entire GDT-based platforms - ImmuniCAR® and OmmniCAR®. This negates increasing concerns over the safety of current alpha beta CAR-T cell therapy approaches. Our proprietary culture media and manufacturing methods overcome the major barriers to commercialising GDT cell therapies, ensuring batch consistency.
TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies. We have a strong focus on chimeric antigen receptor (CAR) modified GDT cells with the aim of treating cancer and major viral diseases. We have a unique technology with a demonstrable safety profile and established intellectual property rights for the entire GDT-based platforms - ImmuniCAR® and OmmniCAR®. This negates increasing concerns over the safety of current alpha beta CAR-T cell therapy approaches. Our proprietary culture media and manufacturing methods overcome the major barriers to commercialising GDT cell therapies, ensuring batch consistency.